Hogan Lovells represents Intellia Therapeutics in life sciences collaboration to create new T-Cell therapy company

Press releases | 16 July 2021

Munich, 16 July 2021 – Global law firm Hogan Lovells represents Intellia Therapeutics in the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company in a collaboration with Blackstone Life Sciences and Cellex Cell Professionals GmbH, the parent company of GEMoaB GmbH (“GEMoaB”), a clinical-stage cell therapy company.

The new company will combine GEMoaB’s clinical-stage universal CAR-T platforms, which are focused on the development of next-generation immunotherapies and cell therapies for hard-to-treat cancers, with Intellia’s differentiated allogeneic cell platform and CRISPR cell engineering. The company will be headquartered in Cambridge, Mass. and will acquire GEMoaB GmbH with its established offices and labs in Dresden, Germany.

The transaction is expected to close in the third quarter of 2021 and is subject to customary closing conditions, including regulatory clearances.

The Hogan Lovells team was led by partner Volker Geyrhalter, and included partners Jörg Schickert, Arne Thiermann, Christian Stoll, and Falk Schöning, senior associates Cornelius Naumann, Julian Fridrich, and Bastian Englisch, and associate Stefan Kirwitzke.

More information is available in the company's press release.